Aktienanalyse zu Precigen Inc (PGEN)PGENPrecigen Inc

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Precigen Inc (PGEN) is a good buy right now due to its recent financial performance, including a reported EPS of $0.05 in Q2 2026, significantly exceeding expectations, and a gross margin of 94.90%. The current price of $6.385 is well below analyst price targets, with B. Riley suggesting a target of $12, representing a potential upside of 88.5%. However, the stock has seen a 5-day change of -18.25%, indicating volatility and potential short-term risks.